Speaker Biographies 

Robert E. Baird, Jr., RN, MSA, CASC, CEO, Dayton Physicians Network
Robert has extensive experience in healthcare management developing strategic plans and directing financial, operational and information technology initiatives.  His successful track record includes increasing revenue, improving efficiency and enhancing patient satisfaction. He is currently CEO of Dayton Physicians Network, one of Ohio's leading multi-specialty cancer treatment centers with thirty-five physicians specializing in Medical Oncology, Radiation Oncology, Urology and Robotics. Dayton Physicians Network has 18 locations and over 350 employees. Robert is intimately involved with all aspects of practice management including researching, designing, planning and implementing healthcare information technology.  Prior to joining Dayton Physicians Network, Robert was Administrator at Samaritan North Surgery Center and Business Manager at Far Hills Surgical Center. He was part of Health Inventures expert team providing strategic and business planning, joint venture formation, facility development and operations management for outpatient surgery centers and surgical hospitals. Robert received his Master of Science in Hospital and Health Service Administration from Central Michigan University, a Bachelor of Science in Education from Bowling Green State University and a Nursing Degree from Excelsior College.

Douglas B. Johnson, M.D., M.S.C.I., Assistant Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center
Dr. Douglas Johnson is currently engaged in clinical and translational research in melanoma and has a broader interest in molecular profiling, targeted therapy, and immune therapy. After completing medical school at UAB and residency at Duke, he has worked with Dr. Jeffrey Sosman and the melanoma team at Vanderbilt for the last several years. His primary interest is in developing and understanding biomarkers for immune and targeted therapeutics and developing clinical trials for melanoma patients. Doug's current efforts include identifying genetic markers for patients receiving immune checkpoint inhibitors, defining the activity of trametinib in melanoma and other cancers with atypical BRAF mutations, and evaluating the effects of molecular profiling in clinical practice. 

Michael Kolodziej, M.D., National Medical Director, Oncology Strategy, Aetna
Dr. Kolodziej is the National Medical Director, Oncology Solutions, Office of the Chief Medical Officer, Aetna. Dr. Kolodziej attended college and medical school at Washington University in St. Louis where he was Phi Beta Kappa and Alpha Omega Alpha. He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia. After completing training, Dr. Kolodziej joined the faculty at the University of Oklahoma School of Medicine where he was an associate professor. He joined New York Oncology in the winter of 1998, and was a partner in the practice until December 2012. He was an active member of the US Oncology Pharmacy and Therapeutics committee, on the executive committee from 2002-2011, and chairman from 2004-2011. He served as Medical Director for Oncology Services for US Oncology from 2007-2011. In this role, he helped direct the implementation of the USON clinical pathways initiative, the integration of the USON EMR into this program, and the development of the USON disease management and advanced care planning programs, now known as Innovent Oncology. He has published several manuscripts and given several presentations on oncology care delivery and reimbursement reform, use of evidence based treatment to enhance value, and personalized medicine. Since joining Aetna in January, 2013, he has been active in Aetna’s oncology delivery reform pilots, pharmacy policy, condition analysis, and genetics subcommittee. He is a Fellow of the American College of Physicians and is a member of the board of the Personalized Medicine Coalition. Dr. Kolodziej is married to Dr. Regina Resta, also a medical oncologist with New York Oncology Hematology, and they have two children, Peter (21) and Katherine (18). 

Shashikant Kulkarni, Ph.D., FACMG, Director, Cytogenomics and Molecular Pathology Program Director, Clinical Genomics Fellowship Program; Associate Professor, Pathology & Immunology, Pediatrics and Genetics, Washington University School of Medicine
Dr. Shashikant Kulkarni is the Director of Cytogenomics and Molecular Pathology at Washington University School of Medicine in St. Louis. He is an Associate Professor in the departments of Pathology & Immunology, Pediatrics and Genetics. He trained at Harvard Medical School, Imperial College, London UK and at AIIMS, India. He is an ABMG Board-certified medical geneticist. In his role, Dr. Kulkarni oversees one of the most modern CLIA certified and CAP accredited state-of-art full-service academic cytogenomics and molecular pathology laboratories in the country, currently staffed by over 150 board certified pathologists, clinical genomocists, clinical bioinformaticists and certified genetic technologists. Full spectrum of Clinical Genomic testing from “Chromosomes to base-pairs” spanning cytogenetics, FISH, chromosomal microarray and Nex-Generation Sequencing (NGS) is performed in the laboratory. Test areas include prenatal diagnostics, perinatal and childhood studies in the evaluation of congenital and developmental disorders, infertility and pregnancy loss studies and cancer. Dr. Kulkarni is actively involved in defining standards for next generation sequencing in clinical diagnostics through his collaboration with the Centers for Disease Control and Prevention through the Clinical Next-Generation-Sequencing Quality Standards National Working Group and is a co-chairman of Clinical Laboratory Standards Institute (CLSI) for microarray-based clinical diagnostics. He also serves on the Scientific Advisory Board of NIH Institute – National Institute of General Medical Science’s Coriell Institute. Dr Kulkarni is considered an expert and key opinion leader in the field of Clinical Genomics and Next Generation Sequencing technology and he has given numerous invited presentations both nationally and internationally. He is on the editorial board of several peer-reviewed journals. Dr Kulkarni is frequently featured in news media for his thoughts and opinions in key publications such as ABC news, CAP today, Nature Medicine, Nature Biotechnology to name a few.
Dr. Kulkarni is the program director of the Clinical Genomics training program at Washington University School of Medicine and trains residents and fellows in clinical genomics. He conducts basic research in genomics of multiple myeloma and acute myeloid leukemia and has published extensively in peer-reviewed articles in journals such as Cell, Nature, Nature Biotechnology, Journal of American Medical Association and New England Journal of Medicine.

Jonathan Pan, Ph.D., MBA, Director, Oncology Companion Diagnostics and Disease Strategy, GlaxoSmithKline
Dr. Pan leads the oncology companion diagnostic and disease strategy within GSK Oncology. In his role, he works closely with diagnostic stakeholders globally, particularly pathologists, oncologists, payors and policy makers to ensure that diagnostic testing is not a barrier to appropriate therapeutic treatments.  His focus is on both currently marketed therapeutics as well as pipeline products to ensure that the proper diagnostic infrastructure is in place in different markets.
Prior to joining GSK, Jonathan helped to establish the pharmaceutical practice at a boutique consulting firm in Boston. There, he worked on innovation, portfolio and competitive strategies for pharmaceutical, medical device and diagnostic companies – looking at unique synergies and opportunities to engage the market. In addition, Jonathan was a senior consultant in IMS Consulting Groups Product and Portfolio Strategy team as well as a consultant in Deloitte Consulting Enterprise Risk Strategy team, servicing Federal Clients such as the Nuclear Regulatory Commission, Health and Human Services and Department of Education.  Jonathan also has experience in due diligence working in the middle markets for large private equity providing leveraged buy-out options or mezzanine financing. Jonathan is a proud University of Michigan graduate earning his Ph.D. in Cellular and Molecular Biology and MBA in management.

Girish Putcha, M.D., Ph.D., Director, Laboratory Science, Palmetto GBA; Founding Medical Director, Orion Genomics and TOMA Biosciences
Girish Putcha is currently Director of Laboratory Science for Palmetto GBA, and the founding Medical Director for Orion Genomics and TOMA Biosciences.
Previously, Girish was the founding laboratory director at Ariosa Diagnostics, Crescendo Bioscience, and Life Technologies, and worked in venture capital at Panorama Capital and RiverVest Venture Partners, focusing on investments in the life sciences. Prior to this, he held various positions at Aviir, CardioDx and VeraCyte, all venture-funded personalized medicine companies.
Girish received a bachelor's degree from Rice University and two master's degrees from the University of London and the Welcome Institute as a Marshall Scholar. He holds medical and doctoral degrees from Washington University School of Medicine, where he also completed a postdoctoral fellowship in molecular neuroscience. Girish completed his postgraduate medical training at the Stanford University School of Medicine, where he also served as adjunct faculty, specializing in molecular genetic pathology.